Memantine shows promise in reducing gambling severity and cognitive inflexibility in pathological gambling: A pilot study

Psychopharmacology

Volumn 212, Issue 4, 2010, Pages 603-612

  Grant, Jon E ^a   Chamberlain, Samuel R ^b   Odlaug, Brian L ^a   Potenza, Marc N ^c   Kim, Suck Won ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Addiction; Cognition; Glutamate; Impulsivity; Pharmacology; Treatment

Indexed keywords

GLUTAMIC ACID; MEMANTINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE SEVERITY; DIZZINESS; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; IMPULSIVENESS; LETHARGY; LIBIDO DISORDER; MALE; NAUSEA; NEUROPSYCHOLOGICAL TEST; OPEN STUDY; OUTCOME ASSESSMENT; PATHOLOGICAL GAMBLING; PILOT STUDY; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; TREATMENT DURATION; YALE BROWN OBSESSIVE COMPULSIVE SCALE MODIFIED FOR PATHOLOGICAL GAMBLING;

ADULT; AGED; BEHAVIOR, ADDICTIVE; COGNITION; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; GAMBLING; HUMANS; MALE; MEMANTINE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PILOT PROJECTS; PSYCHIATRIC STATUS RATING SCALES; RECEPTORS, N-METHYL-D-ASPARTATE; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 78651323502     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-010-1994-5     Document Type: Article

References (46)

1. Aron AR, Robbins TW, Poldrack RA (2004) Inhibition and the right inferior frontal cortex. Trends Cogn Sci 8:170-177
2. Baker DA, McFarland K, Lake RW, Shen H, Toda S, Kalivas PW (2003) N-acetyl cysteine-induced blockade of cocaine-induced reinstatement. Ann NY Acad Sci 1003:349-351
3. Bisaga A, Evans SM (2004) Acute effects of memantine in combination with alcohol in moderate drinkers. Psychopharmacol 172:16-24
4. Black DW (2004) An open-label trial of bupropion in the treatment of pathologic gambling. J Clin Psychopharmacol 24:108-110
5. Black DW, Shaw MC, Allen J (2008) Extended release carbamazepine in the treatment of pathological gambling: An open-label study. Prog Neuropsychopharmacol Biol Psychiatry 32:1191-1194
6. Blanco C, Petkova E, Ibáñez A, Sáiz-Ruiz J (2002) A pilot placebocontrolled study of fluvoxamine for pathological gambling. Ann Clin Psychiatry 14:9-15
7. Cambridge Cognition Limited (2006) CANTABeclipse, version 3. Cambridge Cognition Limited, Cambridge
8. Cunningham-Williams RM, Cottler LB, Compton WM III, Spitznagel EL (1998) Taking chances: Problem gamblers and mental health disorders-results from the St. Louis Epidemiologic Catchment Area study. Am J Publ Health 88:1093-1096
9. Evans SM, Levin FR, Brooks DJ, Garawi F (2007) A pilot doubleblind treatment trial of memantine for alcohol dependence. Alcohol Clin Exp Res 31:775-782
10. Farlow MR, Graham SM, Alva G (2008) Memantine for the treatment of Alzheimer's disease: Tolerability and safety data from clinical trials. Drug Saf 31(7):577-585
11. First MB, Spitzer RL, Gibbon M, Williams JBW (1995) Structured clinical interview for DSM-IV-patient edition (SCID-I/P, Version 2.0). Biometrics Research Department, New York State Psychiatric Institute, New York
12. Frisch MB, Cornell J, Villaneuva M (1993) Clinical validation of the quality of life inventory: A measure of life satisfaction for use in treatment planning and outcome assessment. Psychol Assess 4:92-101
13. Grant JE, Kim SW (2005) Quality of life in kleptomania and pathological gambling. Compr Psychiatry 46:34-37
14. Grant JE, Potenza MN (2006) Compulsive aspects of impulse control disorders. Psychiatr Clin North Am 29:539-551
15. Grant JE, Steinberg MA, Kim SW, Rounsaville BJ, Potenza MN (2004) Preliminary validity and reliability testing of a structured clinical interview for pathological gambling (SCI-PG). Psychiatry Res 128:79-88
16. Grant JE, Levine L, Kim D, Potenza MN (2005) Impulse control disorders in adult psychiatric inpatients. Am J Psychiatry 162:2184-2188
17. Grant JE, Potenza MN, Hollander E, Cunningham-Williams R, Nurminen T, Smits G, Kallio A (2006) A multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling. Am J Psychiatry 163:303-312
18. Grant JE, Kim SW, Odlaug BL (2007) N-acetyl cysteine, a glutamatemodulating agent, in the treatment of pathological gambling: A pilot study. Biol Psychiatry 62:652-657
19. Grant JE, Kim SW, Hartman BK (2008) A double-blind, placebocontrolled study of the opiate antagonist, naltrexone, for the treatment of pathological gambling urges. J Clin Psychiatry 69:783-789
20. Grant JE, Donahue CJ, Odlaug BL, Kim SW, Miller MJ, Petry NM (2009) Imaginal desensitization plus motivational interviewing in the treatment of pathological gambling: A randomized controlled trial. Br J Psychiatry 195:266-267
21. Grant JE, Schreiber L, Odlaug BL, Kim SW (2010) Pathologic gambling and bankruptcy. Compr Psychiatry 51:115-120
22. Guy W (1976) ECDEU assessment manual for psychopharmacology. US Dept Health, Education and Welfare publication (ADM) 76- 338. National Institute of Mental Health, Rockville, pp 218-222
23. Hamilton M (1959) The assessment of anxiety states by rating. Br J Med Psychol 32:50-55
24. Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62
25. Hampshire A, Owen AM (2006) Fractionating attentional control using event-related fMRI. Cereb Cortex 16(12):1679-1689
26. Hampshire A, Chamberlain SR, Monti MM, Duncan J, Owen AM (2010) The role of the right inferior frontal gyrus: Inhibition and attentional control. Neuroimage 50(3):1313-1319
27. Hollander E, Pallanti S, Allen A, Sood E, Baldini Rossi N (2005) Does sustained-release lithium reduce impulsive gambling and affective instability versus placebo in pathological gamblers with bipolar spectrum disorders? Am J Psychiatry 162:137-145
28. Kim SW, Grant JE, Adson DE, Shin YC (2001) Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling. Biol Psychiatry 49:914-921
29. Kim SW, Grant JE, Potenza MN, Blanco C, Hollander E (2009) The Gambling Symptom Assessment Scale (G-SAS): A reliability and validity study. Psychiatry Res 166:76-84
30. Krystal JH, Petrakis IL, Krupitsky E, Schutz C, Trevisan L, D'Souza DC (2003) NMDA receptor antagonism and the ethanol intoxication signal: From alcoholism risk to pharmacotherapy. Ann NY Acad Sci 1003:176-184
31. Lezak MD, Howieson DB, Loring DW, Hannay HJ, Fischer JS (2004) Neuropsychological assessment. Oxford University Press, New York
32. Logan GD, Cowan WB, Davis KA (1984) On the ability to inhibit simple and choice reaction time responses: A model and a method. J Exp Psychol Hum Percept Perform 10:276-291
33. Ma YY, Cepeda C, Cui CL (2009) The role of NMDA receptors in drug addiction. Int Rev Neurobiol 89:131-146
34. Meisner F, Scheller C, Kneitz S, Sopper S, Neuen-Jacob E, Riederer P, Meulen V, Koutsilieri E (2008) Memantine upregulates BDNF and prevents dopamine deficits in SIV-infected macaques: A novel pharmacological action of memantine. Neuropsychopharmacol 33:2228-2236
35. Minkeviciene R, Banerjee P, Tanila H (2008) Cognition-enhancing and anxiolytic effects of memantine. Neuropharmacol 54:1079-1085
36. Owen AM, Roberts AC, Polkey CE, Sahakian BJ, Robbins TW (1991) Extra-dimensional versus intra-dimensional set shifting performance following frontal lobe excisions, temporal lobe excisions or amygdalo-hippocampectomy in man. Neuropsychologia 29(10):993-1006
37. Pallanti S, DeCaria CM, Grant JE, Urpe M, Hollander E (2005) Reliability and validity of the pathological gambling adaptation of the Yale-Brown Obsessive-Compulsive Scale (PG-YBOCS). J Gambl Stud 21:431-443
38. Petry NM (2005) Pathological gambling: Etiology, comorbidity, and treatment. American Psychological Association, Washington
39. Petry NM, Ammerman Y, Bohl J, Doersch A, Gay H, Kadden R, Molina C, Steinberg K (2006) Cognitive-behavioral therapy for pathological gamblers. J Consult Clin Psychol 74:555-567
40. Potenza MN, Fiellin DA, Heninger GR, Rounsaville BJ, Mazure CM (2002) Gambling: An addictive behavior with health and primary care implications. J Gen Intern Med 17:721-732
41. Repantis D, Laisney O, Heuser I (2010) Acetylcholinesterase inhibitors and memantine for neuroenhancement in healthy individuals: A systematic review. Pharmacol Res 61(6):473-481
42. Shaffer HJ, Hall MN, Vander Bilt J (1999) Estimating the prevalence of disordered gambling behavior in the United States and Canada: A research synthesis. Am J Publ Health 89:1369-1376
43. Sheehan DV (1983) The anxiety disease. Scribner's, New York
44. Tait DS, Marston HM, Shahid M, Brown VJ (2009) Asenapine restores cognitive flexibility in rats with medial prefrontal cortex lesions. Psychopharmacol (Berl) 202:295-306
45. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I (2004) Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: A randomized controlled trial. JAMA 291:317-324
46. Van Wageningen H, Jorgensen HA, Specht K, Hugdahl K (2010) A 1H-MR spectroscopy study of changes in glutamate and glutamine (Glx) concentrations in frontal spectra after administration of memantine. Cereb Cortex 20:798-803